Exagen (NASDAQ:XGN) Given New $10.00 Price Target at Canaccord Genuity Group

Exagen (NASDAQ:XGN) had its price objective decreased by Canaccord Genuity Group from $15.00 to $10.00 in a research report released on Wednesday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

Several other equities analysts have also weighed in on the company. BTIG Research reduced their price objective on Exagen from $10.00 to $9.00 and set a “buy” rating for the company in a report on Tuesday. William Blair reaffirmed an “outperform” rating on shares of Exagen in a research report on Tuesday. TD Cowen cut their price target on Exagen from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, February 24th. Craig Hallum decreased their price objective on Exagen from $12.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Exagen in a research note on Wednesday, January 21st. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $9.57.

Exagen Stock Down 4.3%

XGN opened at $3.11 on Wednesday. Exagen has a twelve month low of $2.91 and a twelve month high of $12.23. The company’s 50-day moving average price is $4.18 and its two-hundred day moving average price is $7.50. The stock has a market cap of $70.48 million, a price-to-earnings ratio of -3.38 and a beta of 1.88. The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 1.35.

Exagen (NASDAQ:XGN) last issued its quarterly earnings results on Tuesday, March 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.20). The company had revenue of $16.63 million during the quarter, compared to analyst estimates of $16.46 million. Exagen had a negative net margin of 29.97% and a negative return on equity of 108.93%. As a group, equities analysts expect that Exagen will post -0.88 earnings per share for the current year.

Insider Transactions at Exagen

In other Exagen news, CEO John Aballi sold 15,698 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $3.62, for a total transaction of $56,826.76. Following the sale, the chief executive officer owned 687,299 shares in the company, valued at $2,488,022.38. This represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 12.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Exagen

Several hedge funds have recently made changes to their positions in XGN. Truvestments Capital LLC raised its stake in shares of Exagen by 109.5% during the 4th quarter. Truvestments Capital LLC now owns 6,169 shares of the company’s stock valued at $38,000 after purchasing an additional 3,225 shares during the period. Acadian Asset Management LLC bought a new position in Exagen in the 1st quarter worth about $25,000. Larson Financial Group LLC purchased a new position in Exagen during the 3rd quarter valued at about $105,000. Persistent Asset Partners Ltd purchased a new position in Exagen during the 4th quarter valued at about $80,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of Exagen during the fourth quarter valued at about $82,000. 75.25% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Exagen

Here are the key news stories impacting Exagen this week:

• Positive Sentiment: Record revenue, revenue beat and business highlights: Exagen reported Q4 and full‑year 2025 results showing record total revenue, higher AVISE® CTD average selling price, and >11% annual test volume growth — evidence of operational momentum. Press Release
• Positive Sentiment: 2026 revenue target and commercial investment: Management set a FY26 revenue target of $70M–$73M and is expanding its sales force and product innovation cadence — a growth plan that supports medium‑term upside if execution continues. Article
• Positive Sentiment: Earnings call and materials available: Management discussed strategy and investments on the Q4 call; investors can review the transcript and slide deck for details on margin cadence and commercial progress. Earnings Highlights
• Neutral Sentiment: Q4 EPS in line with expectations: Exagen reported a ($0.20) EPS that met consensus while revenue modestly beat — mixed near‑term financials (beat on revenue, still loss-making). Zacks
• Neutral Sentiment: Guidance slightly below street: FY26 revenue guidance ($70M–$73M) is modestly below the consensus (~$74M), creating uncertainty around near‑term upside until execution is visible. (See Seeking Alpha coverage above.)
• Negative Sentiment: Multiple analyst price‑target cuts: Several firms cut PTs this week (Canaccord and KeyCorp lowered targets from $12–$15 to $10; Craig Hallum to $10; BTIG to $9), which reduces the near‑term analyst valuation runway despite many keeping “buy”/”overweight” ratings. Analyst Notes BTIG/StreetInsider
• Negative Sentiment: Rising short interest: Short interest increased ~21% in February to ~1.07M shares (~5.4% of float) with a ~4 day cover — more shorting raises downward pressure and potential volatility. (Data reported 3/10/2026.)

Exagen Company Profile

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.